Zhongnan Medical Journal Press

Home Results

A total of 21 result was found. Results that relate to Economic

Conflict of interest and economic evidence in Chinese clinical practice guidelines pub-lished in 2018: A survey

Published on New Medicine 2020,30(1):139-158.
5721 times 3187 times

Yan-Bo WANG Qiang WANG Ming-Juan ZHAO Da-Lin HE Yun-Yun WANG

Clinical practice guidelines Conflict of interest Financial resources Economic evidence
Details
Conflict of interest and economic evidence in Chinese clinical practice guidelines published in 2021: a survey

Published on New Medicine 2023,33(1):8-49.
3151 times 1158 times

Yan-Bo WANG Ming-Juan ZHAO Qiang WANG Hui-Zhong XU Hua TAO Jia-Ping GUO Xiu-Sen HUANG Xue-Qun REN Xian-TAO ZENG

Clinical practice guidelines Conflict of interest Economics Financial resources Evidence-based medicine
Details
Pharmacoeconomic evaluation of Huangkui capsule versus losartan potassium tablets in the treatment of IgA nephropathy

Published on Chinese Journal of Pharmacoepidemiology 2023,32(1):02-09.
3820 times 2430 times

Liang-Wen GOU Zhao-Ting GUO Qiong LUO Nan YANG Ming HU

Huangkui capsule Losartan potassium tablets Chronic kidney disease Pharmacoeconomics Cost-utility analysis
Details
Bibliometric analysis of pharmacoeconomics evaluation research in China: based on the Web of Science database

Published on Journal of Mathematical Medicine 2023,36(3):185-193.
2012 times 717 times

Yu-Liang GUI Shi-Qiang XIANG

Pharmacoeconomics evaluation CiteSpace Bibliometrics Visual analysis
Details
Cost-utility analysis of azacitidine versus decitabine in the treatment of myelodysplastic syndrome

Published on Chinese Journal of Pharmacoepidemiology 2023,32(12):1371-1379.
1942 times 663 times

La-Ji DANZENG Yong-Gong YANG Si-Liang WANG Meng-Ying LIU

Azacitidine Decitabine Myelodysplastic syndrome Markov model Cost-utility analysis Pharmacoeconomics
Details
Cost-utility analysis of tislelizumab versus sorafenib as first-line treatment for advanced unresectable hepatocellular carcinoma

Published on Frontiers in Pharmaceutical Sciences 2024,27(1):109-116.
1786 times 624 times

SU Zhan CHE Jinhui PEI Ruifeng

Hepatocellular carcinoma Tislelizumab Sorafenib Partition survival model Pharmacoeconomic analysis
Details
Pharmacoeconomic study of Bailing capsules plus conventional therapy in treating diabetic kidney disease

Published on Chinese Journal of Pharmacoepidemiology 2024,33(3):277-290.
1714 times 573 times

HE Yumei LI Wei ZHU He HAN Sheng

Bailing capsules Diabetic kidney disease Meta-analysis Cost- effectiveness analysis Pharmacoeconomics
Details
Partitioned survival model of pharmacoeconomics evaluation of oncology therapy in R language

Published on Journal of Mathematical Medicine 2024,37(4):240-251.
3684 times 883 times

LIU Jiayi LI Wei

R language Pharmacoeconomics evaluation Health economic evaluation Partitioned survival model Oncology treating drugs
Details
Pharmacoeconomic evaluation of glucagon-like peptide-1 receptor agonist combined with metformin in the treatment of type 2 diabetes mellitus

Published on Chinese Journal of Pharmacoepidemiology 2024,33(4):388-401.
2230 times 1132 times

YU Tian LIU Shaohua WEI Anhua GUO Jieru ZHANG Chengliang LIU Dong LIU Zhelong

Glucagon-like peptide-1 receptor agonist Metformin Type 2 diabetes mellitus Cost-utility Markov model Pharmacoeconomics
Details
Pharmacoeconomic evaluation of aflibercept versus conbercept for the treatment of wet age-related macular degeneration

Published on Frontiers in Pharmaceutical Sciences 2024,27(4):655-662.
2311 times 717 times

LIU Dan ZHANG Bochao ZHANG Jing WANG Juan YUAN Yi GUI Lin CHEN Li

Wet age-related macular degeneration Aflibercept Conbercept Markov model Pharmacoeconomic analysis
Details
Systematic review of studies on the economics of different pharmacy services provided by clinical pharmacists

Published on Frontiers in Pharmaceutical Sciences 2024,27(4):674-683.
2104 times 547 times

Adili·TUERSUN CHENG Gang

Clinical pharmacists Pharmacy services Economics studies Systematic review
Details
Cost-utiliy comparison of ranibizumab or aflibercept in the treatment of diabetic macular edema based on a Markov model

Published on Frontiers in Pharmaceutical Sciences 2024,27(7):1155-1161.
2281 times 446 times

ZHU Yanxia ZHOU Ruting SHI Tianyan

Diabetic macular edema Aflibercept Ranibizumab Pharmacoeconomics
Details
Pharmacoeconomic evaluation of fluticasone furoate/umeclidinium/ vilanterol powder for inhalation for the treatment of chronic obstructive pulmonary disease

Published on Chinese Journal of Pharmacoepidemiology 2024,33(7):721-730.
2466 times 511 times

DING Xueru LIU Huimin HE Xiaodong LI Hua LI Zhihao

Fluticasone furoate/umeclidinium/vilanterol Chronic obstructive pulmonary disease Markov model Cost-utility analysis Pharmacoeconomic
Details
Romiplostim for the treatment of primary immune thrombocytopenia in adults: a rapid health technology assessment

Published on Chinese Journal of Pharmacoepidemiology 2024,33(8):909-918.
3022 times 606 times

LI Jie XIE Jun HAN Yi MENG Ying GAO Liyuan SHI Xiaohui JIANG Zhitao

Romiplostim Primary immune thrombocytopenia Efficacy Safety Economic Rapid health technology assessment
Details
Research progress of equity-informative health economic evaluation

Published on Chinese Journal of Pharmacoepidemiology 2024,33(8):929-937.
2746 times 516 times

FANG Nan HE Xiaoning WU Jing

Economic evaluation Equity Equity-based weighting Distributional cost-effectiveness Extended cost-effectiveness analysis
Details